Drug Search Results
More Filters [+]

Denenicokin

Alternative Names: denenicokin
Latest Update: 2015-03-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CTL Stimulant,NKT Stimulant

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Denenicokin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title